Francesca Fabbri

Meldola, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

The EXcellenT Trial: Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment.

The EXcellenT Trial: Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment.

Journal: Clinical lung cancer

Published: March 28, 2024

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma.

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma.

Journal: International journal of molecular sciences

Published: May 05, 2023

Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.

Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 26, 2020

How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool.

How Many Cancer Clinical Trials Can a Clinical Research Coordinator Manage? The Clinical Research Coordinator Workload Assessment Tool.

Journal: JCO oncology practice

Published: September 16, 2020

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.

Journal: Investigational new drugs

Published: February 24, 2019

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Journal: British journal of haematology

Published: December 02, 2017

A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.

A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.

Journal: The oncologist

Published: February 01, 2015

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.

Journal: Oncotarget

Published: August 13, 2014

Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.

Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.

Journal: Endocrine-related cancer

Published: April 18, 2014

RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.

RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.

Journal: International journal of molecular sciences

Published: April 15, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026